Michael Wilson, MD
Interventional Cardiology · Portland, ORNPI 1871539973
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,400 of the $6,009 with a category attached, or 73.2%. Abbott accounts for 60.8% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2022 at $3,598 and has fallen 99.4% since, to $22 in 2025.
Across 51 payments — averaging $117.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Medicure Pharma Inc.$1K
- Johnson & Johnson$430
- Boston Scientific$202
- Heartflow, Inc.$145
- Abiomed$117
- plus $463 from 11 others
What the payments were for
- Consulting fees$4,40073%
- Food & beverage$1,60927%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 9 | $3,651 |
| Medicure Pharma Inc. | 1 | $1,000 |
| Johnson & Johnson | 17 | $430 |
| Boston Scientific | 3 | $202 |
| Heartflow, Inc. | 1 | $145 |
| Abiomed | 2 | $117 |
| Shockwave Medical, Inc | 2 | $109 |
| Philips North America LLC | 4 | $107 |
| Inari Medical, Inc. | 1 | $55 |
| Medtronic(2 entities) | 3 | $52 |
| Biotronik Inc. | 2 | $33 |
| Cardiovascular Systems Inc. | 1 | $27 |
| BD | 1 | $22 |
| Stryker | 1 | $15 |
| AstraZeneca | 1 | $14 |
| Penumbra, Inc. | 1 | $14 |
| Edwards Lifesciences | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DRAGONFLY OPSTAR$3,400
- Aggrastat (tirofiban HCl)$1,000
- Diamondback Peripheral$167
- CROSSBOSS$140
How this compares
$6,009 in reported general payments places this provider in the 55th percentile of 68 interventional cardiology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 135 | $175,666 |
| EntrestoSacubitril/Valsartan | 21 | $29,853 |
| Repatha SureclickEvolocumab | 12 | $13,421 |
| Repatha SyringeEvolocumab | 12 | $10,994 |
| FarxigaDapagliflozin Propanediol | 11 | $10,819 |
| Atorvastatin Calcium | 339 | $5,578 |
| Metoprolol Succinate | 274 | $5,041 |
| Ezetimibe | 72 | $3,073 |
| Losartan Potassium | 170 | $2,236 |
| Rosuvastatin Calcium | 143 | $1,653 |
| Amlodipine Besylate | 129 | $1,186 |
| Potassium Chloride | 50 | $1,167 |
| Carvedilol | 104 | $1,135 |
| Lisinopril | 105 | $1,097 |
| ClopidogrelClopidogrel Bisulfate | 82 | $1,028 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $14 | $10,81911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 68 interventional cardiology providers in Oregon.
Other interventional cardiology in Portland
- Jason WollmuthPortland$749K
- Ethan KorngoldPortland$407K
- Amish DesaiPortland$186K
- Harsh GolwalaPortland$105K
- Brandon JonesPortland$101K
- Kathryn DawsonPortland$57K
- Logan VincentPortland$42K
- Amged AbdelazizPortland$38K
- Richard SohnPortland$38K
- Daniel FeldmanPortland$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.